uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 01:10PM GMT
Release Date Price: $32.11 (+0.19%)
Luca Issi
RBC Capital Markets, Research Division - Research Analyst

Great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Market. And today is a great privilege to have Matt Kapusta, CEO of UniQure, for a fireside chat. Matt, thanks so much for joining us.

Questions & Answers

Luca Issi
RBC Capital Markets, Research Division - Research Analyst

And maybe let's start with hemophilia B here. Before we go into the specifics, we'd love to pick your brain here at high level on the programs and maybe some of the recent progress that you have made, and then we'll dive into specifics. And thanks again for joining, Matt.

Matthew Craig Kapusta
uniQure N.V. - CEO, CFO & Executive Director

No, really appreciate the invitation, Luca. Thanks for having us. Yes. So I think the most recent news is that we closed our landmark collaboration with CSL, who's going to be our global commercial partner for EtranaDez. So we're really excited about that,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot